Thymidylate kinase: the lost chemotherapeutic target.
Here we highlight the unusual substrate specificity of Plasmodium falciparum thymidylate kinase (PfTMK) and the validity of the enzyme as a new drug target. Furthermore, we predict that the Anaplasma marginale enzyme has attractive domain constituents and may be functionally different from other TMPKs. We postulate that thymidylate kinases could have multiple attractive functions in pathogens and may be a new drug target against numerous microorganisms.
Kandeel
Mahmoud
M
Department of Biomolecular Science, Faculty of Engineering, Center for Advanced Drug Research and Center for Emerging Infectious Diseases and United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu 501-1193, Japan.
Kato
Aya
A
Kitamura
Yoshiaki
Y
Kitade
Yukio
Y
D042322:Anaplasma marginale / Q000201:enzymology; D000962:Antimalarials / Q000737:chemistry / Q000494:pharmacology*; D009703:Nucleoside-Phosphate Kinase / Q000037:antagonists & inhibitors / Q000145:classification / Q000378:metabolism*; D010802:Phylogeny; D010963:Plasmodium falciparum / Q000201:enzymology*; D013379:Substrate Specificity; D013936:Thymidine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology
D000962:Antimalarials; D009703:Nucleoside-Phosphate Kinase; C020093:dTMP kinase; D013936:Thymidine